Get the Stockscreener App
34.75
1.91%
0.65
After Hours:
34.75
Cg Oncology Inc stock is traded at $34.75, with a volume of 194.76K.
It is up +1.91% in the last 24 hours and down -3.98% over the past month.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
See More
Previous Close:
$34.10
Open:
$34.24
24h Volume:
194.76K
Relative Volume:
0.31
Market Cap:
$2.35B
Revenue:
-
Net Income/Loss:
$-64.16M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-69.06M
1W Performance:
+3.82%
1M Performance:
-3.98%
6M Performance:
+7.25%
1Y Performance:
+0.00%
1-Day Range:
$33.95
$34.86
1-Week Range:
$33.06
$35.22
52-Week Range:
$25.77
$50.23
Cg Oncology Inc Stock (CGON) Company Profile
Name
Cg Oncology Inc
Sector
Industry
Phone
(949) 419-6203
Address
400 SPECTRUM CENTER DRIVE, IRVINE
Compare CGON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
34.75 | 2.35B | 0 | -64.16M | -69.06M | -1.2702 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-23-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Jun-28-24 | Initiated | BofA Securities | Buy |
| Feb-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-20-24 | Initiated | Goldman | Neutral |
| Feb-20-24 | Initiated | Morgan Stanley | Overweight |
| Feb-14-24 | Initiated | H.C. Wainwright | Buy |
View All
Cg Oncology Inc Stock (CGON) Latest News
Braidwell LP Sells 138,632 Shares of CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
CG Oncology, Inc. (NASDAQ:CGON) is Ally Bridge Group NY LLC's 4th Largest Position - MarketBeat
CG Oncology, Inc. (NASDAQ:CGON) Holdings Decreased by Yu Fan - MarketBeat
ABG WTT Global Life Science Capital Partners GP Ltd Lowers Position in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
CG Oncology's SWOT analysis: bladder cancer stock poised for pivotal results - Investing.com Australia
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting - Marketscreener.com
CG Oncology to Present Phase 3 Trial Results for Bladder Cancer Treatment at SUO Meeting | CGON Stock News - StockTitan
CG Oncology, Inc. (NASDAQ:CGON) Sees Large Decline in Short Interest - MarketBeat
CG Oncology FY2024 EPS Forecast Boosted by Cantor Fitzgerald - MarketBeat
Los Angeles Capital Management LLC Takes $832,000 Position in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
CG Oncology FY2024 EPS Estimate Increased by HC Wainwright - Defense World
FY2024 EPS Estimates for CG Oncology Raised by HC Wainwright - MarketBeat
CG Oncology FY2024 EPS Estimate Boosted by Lifesci Capital - MarketBeat
CG Oncology, Inc. (CGON) Quarterly 10-Q Report - Quartzy
CG Oncology Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
CG Oncology (NASDAQ:CGON) Releases Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
HC Wainwright Reiterates "Buy" Rating for CG Oncology (NASDAQ:CGON) - MarketBeat
CG Oncology Posts $20.4M Loss, Maintains $540M Cash Reserve Through 2027 | CGON Stock News - StockTitan
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer - The Manila Times
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating - The Bakersfield Californian
CG Oncology, Inc. Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer - Marketscreener.com
TimesSquare Capital Management LLC Purchases 94,010 Shares of CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
CG Oncology, Inc. (NASDAQ:CGON) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Receives $63.88 Consensus Target Price from Analysts - MarketBeat
CG Oncology, first biotech IPO for 2024, surges on trading debut - MSN
Vanguard Group Inc's Strategic Acquisition of CG Oncology Inc Sh - GuruFocus.com
10 Best IPO Stocks To Buy Heading into 2025 - Insider Monkey
CG Oncology To Report Final Results From CORE-001 Bladder Cancer Study Next Month - RTTNews
CG Oncology, Inc. (NASDAQ:CGON) Short Interest Down 14.5% in October - Defense World
UBS Initiates Coverage of CG Oncology (CGON) with Buy Recommendation - MSN
CG Oncology (NASDAQ:CGON) Coverage Initiated by Analysts at UBS Group - MarketBeat
Oncolytic Adenovirus Market Targets USD 250 Billion Valuation by 2033 at a 7.5% of CAGR - PharmiWeb.com
CG Oncology, Inc. (NASDAQ:CGON) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Oncolytic Virus Market Size is Set for Rapid Growth as Innovative - openPR
17,595 Shares in CG Oncology, Inc. (NASDAQ:CGON) Acquired by SG Americas Securities LLC - MarketBeat
Down rounds don’t aid post-IPO performance - BioCentury
CG Oncology (NASDAQ:CGON) Earns "Buy" Rating from Bank of America - MarketBeat
The Potential Rise in the Price of Cg Oncology Inc. (CGON) following insiders activity - Knox Daily
Get in on Cg Oncology Inc.’s (CGON) buy-in window today! - SETE News
Renaissance Technologies LLC Grows Position in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
Marshall Wace LLP Acquires New Shares in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
Companies Like CG Oncology (NASDAQ:CGON) Are In A Position To Invest In Growth - Simply Wall St
Multiple players rev their Engenes in bladder cancer - BioWorld Online
Point72 Asset Management L.P. Sells 75,827 Shares of CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
Want To Improve Study Startup? Get More Efficient - Clinical Leader
We Think CG Oncology (NASDAQ:CGON) Can Afford To Drive Business Growth - Yahoo Finance
How does Cg Oncology Inc. (CGON) change from a tortoise to a hare? - SETE News
RBC Capital Mkts initates Cg Oncology Inc. (CGON) stock to an Outperform - Knox Daily
CG Oncology, Inc. (NASDAQ:CGON) Shares Sold by Perceptive Advisors LLC - MarketBeat
Ensign Peak Advisors Inc Buys New Holdings in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
Cg Oncology Inc Stock (CGON) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):